Acadia Pharmaceuticals' shares fell over 9% following mixed Phase 2 trial results for remlifanserin, a drug for Alzheimer's disease psychosis. The 60 mg dose showed some improvement in hallucinations and delusions but narrowly missed statistical significance, while the 30 mg dose showed little benefit. The company will continue Phase 3 trials, dropping the 30 mg dose and focusing on 60 mg. The drug's safety profile was positive, with no serious side effects or deaths reported. Analysts see the results as a setback but note potential for success in more severe patients in ongoing trials.
ACAD shares trade at USD 23.41 on Pluang as of Sep 24, 2026 22:52 WIB, down 7.94% in one day. The stock's market cap stands at $4.38 billion with a volume of 1,305,789 shares. ACAD's price remains between its 52-week low of $20.06 and high of $30.57, reflecting ongoing investor caution.
